CVS-Mass General Brigham Deal Faces Regulatory Scrutiny Over Rising Healthcare Costs

Last summer, CVS and Mass General Brigham (MGB) announced a strategic partnership aimed at expanding access to primary care in Massachusetts. However, a recent report from the Massachusetts Health Policy Commission (HPC) has raised significant concerns about the deal's potential impact on healthcare spending. The HPC estimates that the transaction could increase residents' healthcare costs by approximately $40 million annually, casting doubt on the partnership's ability to deliver on its promise of improved access.

The proposed integration involves embedding MGB’s clinicians and care pathways into 37 CVS MinuteClinics across Massachusetts. Patients would be referred to MGB’s broader network for follow-up care, a move that regulators fear could shift utilization into a higher-cost system. The business partners filed the necessary paperwork in June of last year, initiating the integration process, which has since been under review by the HPC.

Regulatory Concerns and Cost Projections

The HPC's report, published this month, highlights three primary dynamics contributing to the projected $40 million annual increase in healthcare spending. The first is the cost associated with new primary care patients being treated within MGB’s higher-priced system. According to the HPC, individuals who were not previously MGB patients are expected to receive primary care at MinuteClinics and be billed at MGB's rates. After initial visits, these patients might also be referred to MGB’s more expensive specialists and hospitals.

The HPC's analysis of spending trends for generally low-complexity primary care patients new to the MGB network projects that spending from these patients alone would rise by $27.7 million annually. This significant increase is attributed to the higher costs associated with MGB’s services compared to other providers in the region.

Additionally, the HPC notes that routine convenience care at MinuteClinics could be repriced at higher rates as part of the integration. This adjustment would further contribute to the overall rise in healthcare spending for residents. The third dynamic involves the potential for increased utilization of MGB’s higher-cost services due to the partnership's referral system.

Health economists remain skeptical about whether the deal will effectively expand access to care or simply shift patients into a more expensive healthcare environment. The concern is that while the partnership may increase the number of primary care visits, it could also lead to higher overall spending and costs for both patients and employers.

The Bottom Line

The CVS-Mass General Brigham deal faces significant regulatory hurdles as the HPC's report underscores the potential for increased healthcare costs. While the partnership aims to enhance access to primary care, the projected $40 million annual increase in spending raises questions about its long-term sustainability and benefits for Massachusetts residents. Investors and stakeholders should closely monitor the outcome of the HPC review and any subsequent regulatory actions that may impact the deal's implementation.

The next steps will likely involve further negotiations and possibly adjustments to the integration plan to address the cost concerns raised by the HPC. The success of this partnership will depend on finding a balance between expanding access to care and managing healthcare costs effectively.